^
    4d
    A Single-Arm Prospective Clinical Study of Senaparib as First-Line Maintenance Treatment in HRD-Negative Advanced Epithelial Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer (ChiCTR2600117429)
    P=N/A, N=60, Recruiting, Sun Yat-sen University Cancer Center (Sun Yat-sen University Cancer Hospital, Sun Yat-sen University Cancer Research Institute); Sun Yat-sen Universit
    New trial
    |
    HRD (Homologous Recombination Deficiency) • MUC16 (Mucin 16, Cell Surface Associated)
    |
    HRD
    |
    Paishuning (senaparib)
    4d
    Efficacy and Safety of Senaparib Maintenance Therapy in Patients with p53-Abnormal Endometrial Carcinoma After Adjuvant Chemotherapy (ChiCTR2600116927)
    P=N/A, N=42, Not yet recruiting, Fudan University Shanghai Cancer Center; Fudan University Shanghai Cancer Center
    New trial
    |
    TP53 (Tumor protein P53)
    |
    TP53 mutation
    |
    carboplatin • paclitaxel • Paishuning (senaparib)
    4d
    Study on the efficacy and safety of QL1706 combined with Senaparib in neoadjuvant therapy for ovarian Cancer: A prospective, single-arm clinical study (ChiCTR2600116175)
    P=N/A, N=20, Not yet recruiting, The Fourth Hospital of Hebei Medical University; Fourth Hospital of Hebei Medical University
    New trial
    |
    Paishuning (senaparib) • Qibeian (iparomlimab/tuvonralimab) • iparomlimab (QL1604)
    4d
    A real-world study on the use of Senaparib for first-line maintenance treatment of newly diagnosed BRCAwt advanced epithelial ovarian cancer, primary peritoneal cancer or fallopian tube cancer (ChiCTR2600117526)
    P4, N=50, Not yet recruiting, The Second Affiliated Hospital of Zhejiang University School of Medicine; The Second Affiliated Hospital of Zhejiang University School of Medicine
    New P4 trial
    |
    Paishuning (senaparib)
    4d
    A Single-Center, Prospective Clinical Study of Senaparib Alone or in Combination with Bevacizumab as First-Line Maintenance Therapy in Newly Diagnosed Advanced Homologous Recombination-Proficient (HRP) Ovarian Cancer (ChiCTR2600117644)
    P4, N=50, Not yet recruiting, Guangdong Provincial People's Hospital(Guangdong Academy of Medical Sciences); Guangdong Provincial People's Hospital(Guangdong Academy of Medical Sci
    New P4 trial
    |
    MUC16 (Mucin 16, Cell Surface Associated)
    |
    Avastin (bevacizumab) • Paishuning (senaparib)
    4d
    Multicenter, Single-Arm, Prospective Clinical Study on Senaparib Combined with Bevacizumab for First-Line Maintenance Therapy in Newly Diagnosed BRCA Wild-Type Advanced Ovarian Cancer (ChiCTR2500114463)
    P4, N=62, Recruiting, Women’s Hospital, Zhejiang University School of Medicine; Women’s Hospital, Zhejiang University School of Medicine
    New P4 trial
    |
    MUC16 (Mucin 16, Cell Surface Associated)
    |
    Avastin (bevacizumab) • Paishuning (senaparib)
    2ms
    Poly (ADP-ribose) polymerase (PARP) inhibitors approved for the treatment of cancer. (PubMed, Pharmacol Res)
    The FDA has approved four PARP inhibitors (olaparib, rucaparib, niraparib, and talazoparib) for the treatment of ovarian, breast, prostate, and pancreatic cancer...The Chinese NMPA has approved three PARP antagonists (fuzuloparib, pamiparib, senaparib) for the treatment of ovarian cancer. All seven of these drugs are orally bioavailable and fall within the criteria of Lipinski's rule of five. Drug resistance develops in most PARP-inhibitor-treated cancer patients within one or two years.
    Review • Journal • BRCA Biomarker • PARP Biomarker
    |
    BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • HRD (Homologous Recombination Deficiency)
    |
    Lynparza (olaparib) • Talzenna (talazoparib) • Zejula (niraparib) • Rubraca (rucaparib) • Partruvix (pamiparib) • AiRuiYi (fluzoparib) • Paishuning (senaparib)
    2ms
    Unveiling the power of PARP inhibitors: a meta-analysis on newly diagnosed advanced ovarian cancer maintenance therapy. (PubMed, Expert Rev Anticancer Ther)
    Notably, senaparib showed superior PFS efficacy compared to veliparib and niraparib. PARPi showed efficacy in improving PFS as maintenance therapy for newly diagnosed advanced OC, although no OS advantage was observed. PROSPERO (CRD420251020275).
    Retrospective data • Review • Journal • BRCA Biomarker • PARP Biomarker
    |
    HRD (Homologous Recombination Deficiency) • BRCA (Breast cancer early onset)
    |
    HRD • BRCA wild-type • BRCA mutation
    |
    Zejula (niraparib) • veliparib (ABT-888) • Paishuning (senaparib)
    3ms
    PARP Inhibitor Maintenance After First-Line Chemotherapy in Advanced-Stage Epithelial Ovarian Cancer: A Systematic Review and Meta-Analysis. (PubMed, JAMA Netw Open)
    Observed treatment efficacy and toxic effects varied across PARP inhibitor regimens; for example, the risk ratio for any recurrence or death in the overall study group ranged from 0.53 (95% CI, 0.40-0.70) for senaparib to 0.83 (95% CI, 0.68-1.00) for olaparib, while the risk ratio for high-grade adverse events ranged from 1.15 (95% CI, 0.64-2.06) for veliparib to 4.73 (95% CI, 2.77-8.07) for niraparib. In this study, no subgroup showed an association between first-line PARP inhibitor maintenance therapy in advanced-stage EOC and improved OS, and findings suggest that the consistency of associated PFS benefits may vary, particularly in homologous recombination proficient and BRCA wild type tumors. Variability in efficacy and toxic effects across subgroups and PARP inhibitor regimens underscores the importance of individualized treatment decisions.
    Clinical • Retrospective data • Review • Journal
    |
    HRD (Homologous Recombination Deficiency) • BRCA (Breast cancer early onset)
    |
    HRD • BRCA wild-type
    |
    Lynparza (olaparib) • Zejula (niraparib) • veliparib (ABT-888) • Paishuning (senaparib)
    3ms
    Senaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer with Homologous Recombination Proficient and Exploration of Biomarkers (ChiCTR2500109579)
    P4, N=37, Not yet recruiting, Fudan University Shanghai Cancer Center; Fudan University Shanghai Cancer Center
    New P4 trial
    |
    MUC16 (Mucin 16, Cell Surface Associated)
    |
    Avastin (bevacizumab) • Paishuning (senaparib)
    3ms
    Efficacy and safety of maintenance therapy with senaparib in patients with platinum-sensitive recurrent ovarian cancer previously treated with PARP inhibitors (ChiCTR2500108180)
    P4, N=40, Not yet recruiting, Peking Union Medical College Hospital; Peking Union Medical College Hospital
    New P4 trial • Platinum sensitive
    |
    BRCA (Breast cancer early onset) • MUC16 (Mucin 16, Cell Surface Associated)
    |
    BRCA wild-type • BRCA mutation
    |
    Paishuning (senaparib)
    5ms
    A Study of Absorption-Distribution-Metabolism-Excretion (ADME) of [14C]IMP4297 to China Healthy Male Subjects (clinicaltrials.gov)
    P1, N=6, Completed, Impact Therapeutics, Inc. | Not yet recruiting --> Completed
    Trial completion
    |
    Paishuning (senaparib)